Exact Mass: 402.1063108
Exact Mass Matches: 402.1063108
Found 81 metabolites which its exact mass value is equals to given mass value 402.1063108,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
4-Hydroxy-5-(3',4'-dihydroxyphenyl)-valeric acid-O-glucuronide
C17H22O11 (402.11620619999997)
4-Hydroxy-5-(3,4-dihydroxyphenyl)-valeric acid-O-glucuronide is a conjugate of 4-hydroxy-5-(3,4-dihydroxyphenyl)-valeric acid-O-glucuronide. A glucuronide, also known as glucuronoside, is any substance produced by linking glucuronic acid to another substance via a glycosidic bond. The glucuronides belong to the glycosides. (Wikipedia)
4-Hydroxy-5-(3',5'-dihydroxyphenyl)-valeric acid-O-glucuronide
C17H22O11 (402.11620619999997)
4-Hydroxy-5-(3,5-dihydroxyphenyl)-valeric acid-O-glucuronide is a conjugate of 4-hydroxy-5-(3,5-dihydroxyphenyl)-valeric acid and glucuronide. A glucuronide, also known as glucuronoside, is any substance produced by linking glucuronic acid to another substance via a glycosidic bond. The glucuronides belong to the glycosides. (Wikipedia)
6-[4-(4-carboxy-2-hydroxybutyl)-2-hydroxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
C17H22O11 (402.11620619999997)
6-[4-(4-carboxy-2-hydroxybutyl)-2-hydroxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid is a predicted metabolite generated by BioTransformer¹ that is produced by the metabolism of 5-(3,4-dihydroxyphenyl)-4-hydroxypentanoic acid. It is generated by UDP-glucuronosyltransferase 1-1 (P22309) enzyme via an aromatic-OH-glucuronidation reaction. This aromatic-OH-glucuronidation occurs in humans.
6-[5-(4-carboxy-2-hydroxybutyl)-2-hydroxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
C17H22O11 (402.11620619999997)
6-[5-(4-carboxy-2-hydroxybutyl)-2-hydroxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid is a predicted metabolite generated by BioTransformer¹ that is produced by the metabolism of 5-(3,4-dihydroxyphenyl)-4-hydroxypentanoic acid. It is generated by UDP-glucuronosyltransferase 1-1 (P22309) enzyme via an aromatic-OH-glucuronidation reaction. This aromatic-OH-glucuronidation occurs in humans.
4-Hydroxy-5-(3',5'-dihydroxyphenyl)-valeric acid glucuronide
C17H22O11 (402.11620619999997)
8-p-Coumaroyl-3,4-dihydro-5,7-dihydroxy-4-phenylcoumarin
Calomelanol I
Calomelanol H
Apodanthoside (Not validated)
C17H22O11 (402.11620619999997)
Annotation level-3
3,3-Ethylidenebis(2-methyl-5-hydroxy-1,4-naphthoquinone)
3,6-Ethylidenebis(2-methyl-5-hydroxy-1,4-naphthoquinone)
1-O,2-O-[(1S,2S)-1-(3-acetyl-2,4,6-trihydroxyphenyl)-3-hydroxypropane-1,2-diyl]-beta-D-glucopyranose|1-O,2-O-[(1S,2S)-1-(3-acetyl-2,4,6-trihydroxyphenyl)-3-hydroxypropane-1,3-diyl]-beta-D-glucopyranose|tomentoside II
C17H22O11 (402.11620619999997)
4-Methoxy-benzoic acid 4-(4-methoxy-phenyl)-2-oxo-2H-chromen-7-yl ester
2-Biphenylyl diphenyl phosphate suppliers in China
C24H19O4P (402.10209040000007)
5-O-CARBOMETHOXY-1,2-O-ISO-PROPYLIDENE-3-O-(P-TOLYL-SULFONYL)-ALPHA-D-XYLOFURANOSE
4-[(4-Chlorophenyl) phenylmethyl]-piperidine dihydrochloride
3-Deoxy-3-fluoro-beta-D-ribofuranose 1-acetate 2,5-dibenzoate
4-[[[2-(4-Methoxyphenyl)-3-thiazolidinyl]-sulfanylidenemethyl]amino]benzoic acid ethyl ester
C20H22N2O3S2 (402.10717819999996)
4-(4-methoxyphenyl)-2-oxo-2H-chromen-7-yl 4-methoxybenzoate
4-Hydroxy-5-(3,5-dihydroxyphenyl)-valeric acid glucuronide
C17H22O11 (402.11620619999997)
4-Chloro-3-(1-pyrrolidinylsulfonyl)benzoic acid [2-(butylamino)-2-oxoethyl] ester
C17H23ClN2O5S (402.10161380000005)
3-[[[2-(3-Methylphenyl)-4-quinolinyl]-oxomethyl]amino]-2-thiophenecarboxylic acid methyl ester
(1R,9aR)-octahydro-2H-quinolizin-1-ylmethyl (4-chlorophenoxy)sulfonylcarbamate
C17H23ClN2O5S (402.10161380000005)
4-[[[4-(2-Furanylmethyl)-5-(3-methoxyphenyl)-1,2,4-triazol-3-yl]thio]methyl]benzonitrile
6-[5-(3,4-Dihydroxyphenyl)-4-hydroxypentanoyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
C17H22O11 (402.11620619999997)
4-Hydroxy-5-(3,4-dihydroxyphenyl)-valeric acid-O-glucuronide
C17H22O11 (402.11620619999997)
4-Hydroxy-5-(3,5-dihydroxyphenyl)-valeric acid-O-glucuronide
C17H22O11 (402.11620619999997)
6-[4-(4-carboxy-2-hydroxybutyl)-2-hydroxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
C17H22O11 (402.11620619999997)
6-[5-(4-carboxy-2-hydroxybutyl)-2-hydroxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
C17H22O11 (402.11620619999997)
N-(4-chlorophenoxy)sulfonylcarbamic acid [(1R,9aR)-2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-1-yl]methyl ester
C17H23ClN2O5S (402.10161380000005)
Fuzapladib (sodium)
C15H20F3N3NaO3S (402.10751060000007)
Fuzapladib (IS-741) sodium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib sodium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib sodium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site[1][2].
VU-1545
VU-1545 is a metabotropic glutamate receptor 5 positive allosteric modulator (mGluR5 PAM) with a Ki of 156 nM and an EC50 of 9.6 nM[1].
11-hydroxy-5-methyl-2-[(2r,3s)-2-methyl-3-[(1e)-prop-1-en-1-yl]oxiran-2-yl]-1-oxatetraphene-4,7,12-trione
5-hydroxy-6-[1-(8-hydroxy-3-methyl-1,4-dioxonaphthalen-2-yl)ethyl]-2-methylnaphthalene-1,4-dione
2-{[2-({2-amino-1-hydroxy-4-[methyl(oxo)(phosphonoimino)-λ⁶-sulfanyl]butylidene}amino)-1-hydroxypropylidene]amino}propanoic acid
methyl (1s,4as,7s,7as)-7-formyl-7-hydroxy-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,7ah-cyclopenta[c]pyran-4-carboxylate
C17H22O11 (402.11620619999997)
(3r,5as,6s,10ar)-3-benzyl-1,6-dihydroxy-3,10a-bis(methylsulfanyl)-5ah,6h,10h-pyrazino[1,2-a]indol-4-one
C20H22N2O3S2 (402.10717819999996)
(1s,4as,7s,7as)-4-(methoxycarbonyl)-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,7h,7ah-cyclopenta[c]pyran-7-carboxylic acid
C17H22O11 (402.11620619999997)
4-(methoxycarbonyl)-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,7h,7ah-cyclopenta[c]pyran-7-carboxylic acid
C17H22O11 (402.11620619999997)
methyl 7-formyl-7-hydroxy-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,7ah-cyclopenta[c]pyran-4-carboxylate
C17H22O11 (402.11620619999997)
5-hydroxy-6-[1-(1-hydroxy-6-methyl-5,8-dioxonaphthalen-2-yl)ethyl]-2-methylnaphthalene-1,4-dione
3-benzyl-1,6-dihydroxy-3,10a-bis(methylsulfanyl)-5ah,6h,10h-pyrazino[1,2-a]indol-4-one
C20H22N2O3S2 (402.10717819999996)
(7s,13r)-9-hydroxy-7-(4-hydroxyphenyl)-13-phenyl-4,14-dioxatricyclo[8.4.0.0³,⁸]tetradeca-1,3(8),9-triene-5,11-dione
(7r,13s)-9-hydroxy-13-(4-hydroxyphenyl)-7-phenyl-4,14-dioxatricyclo[8.4.0.0³,⁸]tetradeca-1,3(8),9-triene-5,11-dione
11-hydroxy-5-methyl-2-{2-methyl-3-[(1z)-prop-1-en-1-yl]oxiran-2-yl}-1-oxatetraphene-4,7,12-trione
9-hydroxy-7-(4-hydroxyphenyl)-13-phenyl-4,14-dioxatricyclo[8.4.0.0³,⁸]tetradeca-1,3(8),9-triene-5,11-dione
(1s,4as,7as)-7-(methoxycarbonyl)-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carboxylic acid
C17H22O11 (402.11620619999997)
methyl (1s,4ar,7r,7as)-7-formyl-7-hydroxy-1-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,7ah-cyclopenta[c]pyran-4-carboxylate
C17H22O11 (402.11620619999997)
5,6,11-trihydroxy-9-methoxy-22-oxahexacyclo[10.10.2.0²,⁷.0⁸,²⁴.0¹⁵,²³.0¹⁶,²¹]tetracosa-2(7),3,5,8(24),9,11,16,18,20-nonaen-13-one
1-{3-[(2s,3s,4ar,6r,7s,8s,8ar)-7,8-dihydroxy-2,6-bis(hydroxymethyl)-hexahydro-2h-pyrano[2,3-b][1,4]dioxin-3-yl]-2,4,6-trihydroxyphenyl}ethanone
C17H22O11 (402.11620619999997)
(1r,15s,23s)-5,6,11-trihydroxy-9-methoxy-22-oxahexacyclo[10.10.2.0²,⁷.0⁸,²⁴.0¹⁵,²³.0¹⁶,²¹]tetracosa-2(7),3,5,8(24),9,11,16,18,20-nonaen-13-one
5-hydroxy-3-[1-(8-hydroxy-3-methyl-1,4-dioxonaphthalen-2-yl)ethyl]-2-methylnaphthalene-1,4-dione
(1s,4as,7as)-7-(methoxycarbonyl)-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carboxylic acid
C17H22O11 (402.11620619999997)
4-(methoxycarbonyl)-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,7h,7ah-cyclopenta[c]pyran-7-carboxylic acid
C17H22O11 (402.11620619999997)
11-hydroxy-5-methyl-2-[2-methyl-3-(prop-1-en-1-yl)oxiran-2-yl]-1-oxatetraphene-4,7,12-trione
5-hydroxy-6-[(1s)-1-(8-hydroxy-3-methyl-1,4-dioxonaphthalen-2-yl)ethyl]-2-methylnaphthalene-1,4-dione
(1r,4as,7r,7as)-4-(methoxycarbonyl)-1-{[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,7h,7ah-cyclopenta[c]pyran-7-carboxylic acid
C17H22O11 (402.11620619999997)
7-(methoxycarbonyl)-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carboxylic acid
C17H22O11 (402.11620619999997)